Europe syndromic multiplex diagnostic market is projected to register a CAGR of 7.0% in the forecast period of 2020 to 2027. The new market report contains data for historic year 2018, the base year of calculation is 2019 and the forecast period is 2020 to 2027.
Market Segmentation:
Syndromic multiplex diagnostic is a type of advanced diagnostic test which is utilized for the detection of various types of infection diseases such as infective gastroenteritis, respiratory infection, childhood infections, meningitis, sexually transmitted infections, immunosuppression, hepatitis, eye infections and tropical fever, among other types of infectious diseases. Syndromic multiplex diagnostic test also helps clinicians, healthcare and hospitals for detection of the symptoms and signs of the various types of infectious diseases. In the syndromic multiplex diagnostic, various types of reagents and consumables and instruments and accessories are used which helps in maintaining the accuracy and provide fast diagnosis results. The syndromic multiplex diagnostic testing is used to diagnose of 22 respiratory pathogens simultaneously.
Some of the major factors contributing to the growth of the Europe syndromic multiplex diagnostic market are:
- growing adoption of molecular diagnostics growing adoption of molecular diagnostics
- Growing prevalence of infection diseases
Market Players:
The key market players for Europe syndromic multiplex diagnostic market are listed below:
- GenMark Diagnostics, Inc.
- QuantuMDx Group Ltd.
- BioFire Diagnostics (a subsidiary of bioMerieux SA)
- Bio-Rad Laboratories, Inc.
- Thermo Fisher Scientific Inc.
- Siemens Healthcare GmbH
- QIAGEN
- Hologic, Inc.
- F. Hoffmann-La Roche Ltd
- BD
- Danaher
- Curetis
- Abbott
- DiaSorin S.p.A.
- Bosch Healthcare Solutions GmbH (a subsidiary of Robert Bosch GmbH)
- Biocartis
- Luminex Corporation
- Seegene Inc.